title: Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
authors.forename: Gianluca
authors.initials: G
authors.lastname: Trifirò
authors.forename: Letterio
authors.initials: L
authors.lastname: Morgante
authors.forename: Michele
authors.initials: M
authors.lastname: Tari
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Arcoraci
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Savica
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077465:Cabergoline; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004873:Ergolines / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004873:Ergolines; D010479:Pergolide; D000077465:Cabergoline